Rituximab Treatment in Neuromyelitis Optica Spectrum Disorders

Based on a meta-analysis and review of rituximab use in the treatment of neuromyelitis optica spectrum disorders, the authors reported that rituximab was efficacious in reducing relapse rate and disability, but cautioned about potential side effects and adverse events, especially when considering rituximab as first-line therapy.